Simcere and Connect Biopharma’s Rademikibart NDA Accepted by China’s NMPA for Atopic Dermatitis
The New Drug Application (NDA) for rademikibart, an anti-inflammatory monoclonal antibody (mAb) co-developed by China’s...
NASDAQ: CNTB
Connect Biopharma Shifts Focus to US, Plans Further Reduction in China Workforce
Connect Biopharma Holdings Ltd (NASDAQ: CNTB), a Sino-US biotechnology company that initially operated in Suzhou...
Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China
China’s Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into an agreement to acquire the...
Connect Biopharma Completes Phase I Trial of CBP-174 for Itch in Skin Diseases
Sino-US biotech Connect Biopharma Holdings Ltd (NASDAQ: CNTB), headquartered in San Diego, California, and Taicang,...